GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Dimethylfumarat, ATC L04AX07

Health · Germany government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

January 31, 2027
Response Due
Active
Status

Opportunity Overview

Germany – Pharmaceutical products – Open house drug discount agreements for the active ingredient dimethyl fumarate, ATC L04AX07

This Germany Pharmaceuticals opportunity is one most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedFebruary 10, 2025
Procurement stageActive solicitation
Response dueJanuary 31, 2027
StatusOpen — accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedSeptember 22, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Related Opportunities in Germany

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Liraglutid, ATC A10BJ02 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient pasireotide, ATC H01CB05, for the period 01.02.2026 - 31.01.2028
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Eisen (parenterale Zubereitungen), ATC B03AC01 f. d. Z. 01.11.25-31.10.27 (zzgl.Verlängerungsoption 1x12 Mon)
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Diclofenac (ausschließlich GEL 25 g), ATC D11AX18 für die Zeit 01.04.2025 - 31.03.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Doravirin + Lamivudin + Tenofovirdisoproxilfumarat, ATC J05AR24 für die Zeit 01.12.2025 - 30.11.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Kaliumiodid, ATC H03CA01 für die Zeit 01.03.2026 - 29.02.2028 (zzgl. Verlängerungsoption 1x12 Monate)
Germany – Pharmaceutical products – Conclusion of a non-exclusive discount agreement pursuant to Section 130a Paragraph 8 of the German Social Code, Book V (SGB V) for the active ingredient buserelin, ATC L02AE01, for the period 01.01.2026 - 31.12.2027
Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Natriumphenylbutyrat, ATC A16AX03 für die Zeit 01.11.2025 - 31.10.2027

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.